Literature DB >> 24583763

β-cell function after weight-loss induced by bariatric surgery.

Adrian Vella.   

Abstract

Mesh：

Year:  2014        PMID： 24583763      PMCID： PMC4073942          DOI： 10.1152/physiol.00003.2014

Source DB:  PubMed          Journal:  Physiology (Bethesda)        ISSN： 1548-9221


× No keyword cloud information.
  28 in total

1.  Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus.

Authors:  P Shah; A Vella; A Basu; R Basu; W F Schwenk; R A Rizza
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

2.  Gastric bypass and nesidioblastosis--too much of a good thing for islets?

Authors:  David E Cummings
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

3.  Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover.

Authors:  Juris J Meier; Alexandra E Butler; Ryan Galasso; Peter C Butler
Journal:  Diabetes Care       Date:  2006-07       Impact factor: 19.112

4.  The prevalence of obesity and obesity-related health conditions in a large, multiethnic cohort of young adults in California.

Authors:  Corinna Koebnick; Ning Smith; Karl Huang; Mayra P Martinez; Heather A Clancy; Lawrence H Kushi
Journal:  Ann Epidemiol       Date:  2012-07-04       Impact factor: 3.797

5.  Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study.

Authors:  Kusal Wickremesekera; Geoff Miller; Tissa Desilva Naotunne; Graham Knowles; Richard S Stubbs
Journal:  Obes Surg       Date:  2005-04       Impact factor: 4.129

6.  Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery.

Authors:  Geoffrey J Service; Geoffrey B Thompson; F John Service; James C Andrews; Maria L Collazo-Clavell; Ricardo V Lloyd
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

7.  How do we define cure of diabetes?

Authors:  John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

8.  Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study.

Authors:  Christopher D Still; G Craig Wood; Peter Benotti; Anthony T Petrick; Jon Gabrielsen; William E Strodel; Anna Ibele; Jamie Seiler; Brian A Irving; Melisa P Celaya; Robin Blackstone; Glenn S Gerhard; George Argyropoulos
Journal:  Lancet Diabetes Endocrinol       Date:  2014-01       Impact factor: 32.069

9.  GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery.

Authors:  Amanda Jiménez; Roser Casamitjana; Judith Viaplana-Masclans; Antonio Lacy; Josep Vidal
Journal:  Diabetes Care       Date:  2013-01-28       Impact factor: 19.112

10.  Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.

Authors:  Nils B Jørgensen; Carsten Dirksen; Kirstine N Bojsen-Møller; Siv H Jacobsen; Dorte Worm; Dorte L Hansen; Viggo B Kristiansen; Lars Naver; Sten Madsbad; Jens J Holst
Journal:  Diabetes       Date:  2013-05-06       Impact factor: 9.461
View more
  2 in total

Review 1.  Bariatric Surgery Resistance: Using Preoperative Lifestyle Medicine and/or Pharmacology for Metabolic Responsiveness.

Authors:  Nicole M Gilbertson; Andrew S Paisley; Sibylle Kranz; Arthur Weltman; Jennifer L Kirby; Peter T Hallowell; Steven K Malin
Journal:  Obes Surg       Date:  2017-12       Impact factor: 4.129

2.  Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats.

Authors:  Ananyaa Sridhar; Dawood Khan; Mahmoud Abdelaal; Jessie A Elliott; Violetta Naughton; Peter R Flatt; Carel W Le Roux; Neil G Docherty; Charlotte R Moffett
Journal:  PLoS One       Date:  2022-09-22       Impact factor: 3.752
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.